Efficacy and Safety Of a New Olopatadine Hydrochloride, 0.77% Ophthalmic Formulation In Patients With Allergic Conjunctivitis Using The Conjunctival Allergen Challenge (CAC) Model (NCT01479374)

被引：0

作者：

Torkildsen, Gail ^{[1
]}

Macejko, Thomas ^{[2
]}

Narvekar, Abhijit ^{[3
]}

Bergmann, Mark ^{[4
]}

机构：

[1] Andover Eye Associates, Andover, MA USA

[2] Apex Eye, Fairfield, OH USA

[3] Alcon Labs Inc, Ft Worth, TX 76101 USA

[4] Apex Eye, Cincinnati, OH USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2014年 / 133卷 / 02期

关键词：

D O I：

10.1016/j.jaci.2013.12.982

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

957

引用

页码：AB277 / AB277

页数：1

共 30 条

[1] Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
Torkildsen, Gail
Narvekar, Abhijit
Bergmann, Mark
CLINICAL OPHTHALMOLOGY, 2015, 9 : 1703 - 1713
[2] Phase 3 Study of Efficacy and Safety of Once-daily Olopatadine Hydrochloride, 0.77% Ophthalmic Formulation in Patients With Allergic Conjunctivitis Using the Ora Conjunctival Allergen Challenge Model (Ora-CAC™☆) (NCT01743027)
McLaurin, Eugene
Narvekar, Abhijit
Gomes, Paul J.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
[3] Phase III study of new high-dose olopatadine 0.77% formulation in patients with allergic conjunctivitis using the conjunctival allergen challenge model
Torkildsen, G.
ALLERGY, 2013, 68 : 650 - 651
[4] POOLED ANALYSIS OF 2 CONFIRMATORY TRIALS EVALUATING THE EFFICACY AND SAFETY OF OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION 0.77% USING A CONJUNCTIVAL ALLERGEN CHALLENGE MODEL
McLaurin, Eugene B.
Narvekar, Abhijit
Adewale, Adeniyi
Gomes, Paul J.
Torkildsen, Gail
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
[5] Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model
McLaurin, Eugene
Narvekar, Abhijit
Gomes, Paul
Adewale, Adeniyi
Torkildsen, Gail
CORNEA, 2015, 34 (10) : 1245 - 1251
[6] Clinical efficacy of olopatadine and epinastine in allergic conjunctivitis subjects defined by sensitivity to conjunctival allergen challenge (CAC)
D'Arienzo, PA
Granet, D
Epstein, AB
Lanier, BQ
Finegold, I
Ledgerwood, GL
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
[7] Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge
Fujishima, Hiroshi
Ohashi, Yuichi
Takamura, Etsuko
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (04) : 476 - 481
[8] Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model
Spangler, DL
Bensch, G
Berdy, GJ
CLINICAL THERAPEUTICS, 2001, 23 (08) : 1272 - 1280
[9] Efficacy and safety of ophthalmic epinastine evaluated using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis
Schiffman, RM
Abelson, MB
Crampton, HJ
Slugg, AP
Michaelson, C
Bradford, RR
Kim, B
Lue, JC
Whitcup, SM
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U17 - U17
[10] A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model
Greiner, JV
Udell, IJ
CLINICAL THERAPEUTICS, 2005, 27 (05) : 568 - 577

← 1 2 3 →